CLLANZ Newsletter

Budget 2026

As I think was largely anticipated there is unlikely to be any further funding of new CLL Drugs in the immediate future. Pharmac has received an increase of $54 million over the next four years ($13.5m per year) which will barely keep pace with price increases.

New CLL drugs funded from 1 May

However, we were thrilled to confirm last month that from 1 May 2026, Pharmac is funding modern combination therapies (venetoclax with ibrutinib or obinutuzumab) as first-line treatment and widening access to ibrutinib for second-line use.

These are time-limited, targeted treatments that can reduce reliance on chemotherapy and, in many cases, avoid prolonged hospital-based infusions. That’s better outcomes for patients, and less strain on the system.

Some of our members have already benefited from this change. RIP FCR we hope!

Blood Cancer Alliance

We are active members of the Blood Cancer Alliance which is of great benefit to us. We participate in monthly Teams calls with Tim Edmonds and Rosie Shaw from Blood Cancer NZ along with other organisations such as Myeloma NZ. At our most recent meeting, Rosie Shaw, who leads BCNZ’s Advocacy activities briefed us on policies being developed by the various political parties leading up to this year’s general election.

In summary, Act, Greens and National are all supportive of increased investment in medicines, Labour is focused on primary health care and NZ First’s position on medicines is unclear.

We will continue to fight for funding for drugs such as Acalabrutinib, Pirtobrutinib and Zanubrutinib.

BCNZ Patient Forum

This year’s Forum is being held at the Grand Chancellor Hotel, Wellington, on 11-12 September.

https://www.bloodcancerpatientforum.org.nz/

King’s Birthday Weekend

Have a great break everyone.

CLL Advocates